Business
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Significant progress advancing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) Quarter marked by
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Significant progress advancing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM)\nQuarter marked by expansion into Europe with multiple clinical trial sites approved for enrollment \n29 of 68 clinical sites now enrolling patients across the U.S. and Europe\nInterim analysis, planned when 30-50% of subjects reach 6 months in study expected mid-year 2023\nHOUSTON, Nov. 14, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended September 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.\n\n \n \n \n \n \n \n\n \n\"In the past quarter, we successfully expanded our potentially pivotal Berubicin trial into Europe with a number of clinical sites initiated and most recently the initiation of patient enrollment and dosing in France. This expansion into Europe drives us toward our goal of interim analysis, expected in mid-2023, which we believe has the potential to be transformational milestone. Moving forward, we are focused on building momentum and advancing this important program across the finish line,\" commented John Climaco, CEO of CNS Pharmaceuticals.\nBerubicin Highlights Ongoing potentially pivotal trial evaluating lead product candidate Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) \n Upcoming Milestones\nContinued site initiations across the U.S., Italy, France, Spain, and Switzerland for potentially pivotal study to evaluate efficacy of Berubicin in the treatment of adult GBM;Regulatory and ethics approval in Italy;Interim analysis of the trial when 30-50% of the total expected patients have been on study for 6 months (expected mid-year 2023); andComplete enrollment in potentially pivotal clinical trial for GBM.The FDA has granted CNS Pharmaceuticals Fast Track Designation and Orphan Drug Designation for Berubicin. For more information about the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069.\nSummary of Financial Results for the Th...